A Randomised, Open-Label, Multi-Centre Phase II Study of BAY 43-9006 ( Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.

Trial Profile

A Randomised, Open-Label, Multi-Centre Phase II Study of BAY 43-9006 ( Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Sorafenib (Primary) ; Interferon alpha-2a
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 02 Feb 2009 Status changed from active, no longer recruiting to completed.
    • 26 Jan 2009 Results were published in the Journal of Clinical Oncology in Jan 2009.
    • 28 Sep 2008 Planned end date changed from 1 Mar 2008 to 1 Apr 2009 according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top